It may be noted that the percentages of IL-10+ B cells after collagen epitope stimulation were shown to be reduced in RA patients and that tofacitinib treatment partially prevented this IL-10 downmodulation [30], indicating that tofacitinib may also function to promote IL-10 expression in certain situations. This evidence concerns the gene IL10 and rheumatoid arthritis.